Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of recombinant protein VO and its preparation method and application

A technology of recombinant protein and Escherichia coli, applied in chemical instruments and methods, recombinant DNA technology, pharmaceutical formulations, etc., can solve the problem of preparing antibodies without OmpA protein, achieve good immune protection effect, maintain spatial conformation and immunogenicity, The effect of mild purification conditions

Inactive Publication Date: 2019-06-07
ARMY MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the preparation of antibodies based on OmpA protein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of recombinant protein VO and its preparation method and application
  • A kind of recombinant protein VO and its preparation method and application
  • A kind of recombinant protein VO and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Gene synthesis and subcloning

[0040] 1. According to figure 1 Based on the design idea, the recombinant protein Vo containing Loop1, Loop2, Loop3, Loop4 and protein linker was designed. The synthesis of DNA encoding Vo and the connection of sequence and pGEX-6p-2 were synthesized by Shanghai Sangong Bioengineering Co., Ltd.

[0041] 2. Transformation of recombinant plasmids

[0042] Take 3 tubes of Escherichia coli XL1blue competent cells (Shanghai Chaoyan Biotechnology Co., Ltd.) from the -80°C refrigerator, and add pGEX-6P-2 plasmid (GE Healthcare Life Sciences) to the first tube as a positive control; add 1ulVo to the second tube Synthetic plasmid; no exogenous DNA was added to the third tube as a negative control. Ice bath for 50min, heat shock in 42℃ metal bath for 90s, rapid ice bath for 2min. Add 600 μl LB blank medium, mix well, and shake at 220rp for 1 hour in a shaker at 37°C.

[0043] Each tube was centrifuged at 5000 rpm for 3 min at room t...

Embodiment 2

[0049] Example 2 Induced expression, purification and identification of expression form of recombinant fusion protein Vo in prokaryotic expression system-Escherichia coli

[0050] 1. Vo-induced expression

[0051] 1) Take 100 μL of the overnight cultured pGEX-6P-2-Vo / XL-1blue bacterial solution and add it to 10 mL of Amp+ resistant LB medium, culture overnight at 180 rpm at 37°C, take 400 μL of the overnight cultured bacterial solution and add 20 mL of Amp+ resistant LB medium (the rest of the bacterial solution was stored in a refrigerator at 4°C for later use), cultured at 37°C for 2-3 hours at a rotational speed of 200 rpm, and when the secondary activation reached OD600 of 0.8-1.0, 4 μL of IPTG was added to make the final concentration 200 μM. Then place on a shaking table to induce expression at 30°C for 3h.

[0052] 2) Take out the bacterial solution after induced expression, centrifuge at 12,000rpm for 5min, discard the supernatant, add 1mL lysisbuffer (20mM PB, pH 7...

Embodiment 3

[0059] Example 3 Preparation of Vo antigen

[0060] 1. Amplify culture to obtain protein

[0061] Take 400 μL of the spare pGEX-6P-2-Vo / XL-1blue bacterial solution stored in a 4°C refrigerator and add it to 20 mL of LB medium containing Amp resistance for one activation. Add the primary activated bacterial solution to 400mL LB medium containing Amp resistance for secondary activation, culture at 37°C for 3-4h until the OD600 is 1.0, add 80μLPTG (final concentration is 200μM) and place in a shaker at 16°C overnight After induction, 12000rpm was centrifuged for 15min to collect the thalline, and after adding 20mL lysis buffer (same as Example 2) to resuspend the thallus, the bacterium liquid was subjected to ultrasonic lysis for 3min (200V), and the supernatant and 800 μL of GST fusion protein were collected. Glutathione Sepharose 4B (GE Company) gel beads (beads) binding treatment; then SDS-PAGE gel electrophoresis.

[0062] 2. Use the enzyme digestion method to separate th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a recombinant protein Vo. The recombinant protein Vo is formed by fusing extramembranous segments of outer membrane protein A (OmpA) of Meningitic E. coil K1 through connecting peptides. The general formula of the recombinant protein Vo is loop1-(linker a)n1-loop2-(linker b)n2-loop3-(linker b)n3-loop4-(linker a)n4-loop1-(linker a)n5-loop2-(linker b)n6-loop3-(linker b)n7-loop4. The invention also provides a preparation method and application of the recombinant protein. The recombinant protein Vo can be used for preparing diagnostic reagents and preventing or therapeutic drugs, and has favorable immunoprotection effects for resisting E. coli K1 infection.

Description

technical field [0001] The invention belongs to the field of biotechnology and pharmacy, and relates to a recombinant meningitidis Escherichia coli K1 vaccine protein Vo, and further relates to a preparation method and application of the recombinant protein. Background technique [0002] Bacterial meningitis is a common infectious disease in newborns and the main cause of neonatal death and long-term disability. According to the World Health Organization, the incidence of neonatal bacterial meningitis ranks among the top five neonatal infectious diseases, and its mortality rate is as high as 40%. Due to the increase of premature babies and other reasons, the incidence of neonatal bacterial meningitis in my country has gradually increased, and it has become one of the three major causes of neonatal hospitalization. With the spread of antibiotic resistance, the efficacy and prognosis of neonatal bacterial meningitis are even less optimistic. Data show that about 1% -40% of n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/63G01N33/68G01N33/569A61K39/108A61P31/04
CPCA61K39/0258A61K2039/55505C07K14/245C07K2319/00G01N33/56911G01N33/68Y02A50/30
Inventor 顾江魏超顾浩赵莉群杨峰高晨敬海明邹全明
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com